Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren’s syndrome

Garlapati, Komali; Kammari, Anuja; Badam, Raj Kumar; Surekha, B E; Boringi, Mamatha; Soni, Pratima

doi:10.1080/08923973.2019.1593448

Cited by 8 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current treatments include oral swabs, lip moisturizers, topical saliva substitutes, muscarinic agonists, scheduled use of ice water, electrostimulation, and acupuncture [71,72]. Though not life-threatening, dysphagia and awakening from sleep due to oral dryness are debilitating consequences of xerostomia [73], which beg the advancement of drug therapies beyond symptom relief [74]. This section reviews the possible molecular targets that should be investigated.…”

Section: Dry Mouth (Xerostomia)mentioning

confidence: 99%

The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology

Zeng

Zhou

et al. 2022

IJMS

View full text Add to dashboard Cite

Primary Sjögren’s syndrome (pSS) is a chronic, systemic autoimmune disease defined by exocrine gland hypofunction resulting in dry eyes and dry mouth. Despite increasing interest in biological therapies for pSS, achieving FDA-approval has been challenging due to numerous complications in the trials. The current literature lacks insight into a molecular-target-based approach to the development of biological therapies. This review focuses on novel research in newly defined drug targets and the latest clinical trials for pSS treatment. A literature search was conducted on ClinicalTrials.gov using the search term “Primary Sjögren’s syndrome”. Articles published in English between 2000 and 2021 were included. Our findings revealed potential targets for pSS treatment in clinical trials and the most recent advances in understanding the molecular mechanisms underlying the pathogenesis of pSS. A prominent gap in current trials is in overlooking the treatment of extraglandular symptoms such as fatigue, depression, and anxiety, which are present in most patients with pSS. Based on dryness and these symptom-directed therapies, emerging biological agents targeting inflammatory cytokines, signal pathways, and immune reaction have been studied and their efficacy and safety have been proven. Novel therapies may complement existing non-pharmacological methods of alleviating symptoms of pSS. Better grading systems that add extraglandular symptoms to gauge disease activity and severity should be created. The future of pSS therapies may lie in gene, stem-cell, and tissue-engineering therapies.

show abstract

Section: Dry Mouth (Xerostomia)mentioning

confidence: 99%

The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology

Zeng

Zhou

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Salivary hypofunction leads to xerostomia in pSS patients. Dysphonia, dysphagia, stomatopyrosis (burning mouth), dysgeusia (altered taste), teeth erosion and oral infections are common problems caused by xerostomia [60].Current treatment include oral swabs, lip moisturizers, topical saliva substitutes, muscarinic agonists, scheduled use of ice water, electrostimulation and acupuncture [71,72].Though not life-threatening, dysphagia and awakening from sleep due to oral dryness are debilitating consequences of xerostomia [73] which beg the advancement of drug therapies beyond symptom relief [74].This section reviews the possible molecular targets that should be investigated.…”

Section: Dry Mouth (Xerostomia)mentioning

confidence: 99%

The Future of Targeted Treatment of Primary Sjögren's Syndrome: A Focus on Extra-Glandular Pathology

Zeng¹,

Zhou²,

Liu³

et al. 2022

Preprint

View full text Add to dashboard Cite

Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease defined as exocrine gland hypofunction resulting in dry eyes and dry mouth. Recent interest in biological therapies for pSS has been garnered, however achieving FDA-approval has been challenging due to the numerous complications in the trials. Current literature lacks insight and a molecular target-based approach to the development of biological therapies. This review focuses on novel research in newly defined drug targets and latest clinical trials for pSS treatment. A literature search was conducted on ClinicalTrials.gov using the search term “Primary Sjögren's syndrome”. Articles published between 2000 and 2021 in English language were included. Our findings revealed the potential targets for pSS treatment in clinical trials and the most recent advances in understand-ing of molecular mechanisms underlying the pathogenesis of pSS. A prominent gap in current trials is overlooking the treatment of extraglandular symptoms such as fatigue, depression and anxiety which pervade most patients with pSS. Based on dryness and these symptom-directed therapies, emerging biological agents targeting inflammatory cytokines, signal pathways and immune reaction have been studied and proved the efficacy and safety. Novel therapies may complement existing non-pharmacological methods of alleviating symptoms of pSS. Better grad-ing systems adding extraglandular symptoms to gauge disease activity and severity should be created. The future of pSS therapies may lie in gene therapy, stem cell and tissue engineering ther-apy.

show abstract

“…[ 28 ] A recent meta-analysis has confirmed that INF-α at a dose of 150 IU three times daily is effective in increasing salivary production and flow rate and modifies the immunomodulatory action in SS patients with minimal side effects. [ 29 ]…”

Section: S Alivary E Nhancement T Herapiesmentioning

confidence: 99%

Artificial Saliva for Therapeutic Management of Xerostomia

Alhejoury¹,

Mogharbel²,

Al-Qadhi

et al. 2021

Journal of Pharmacy and Bioallied Sciences

View full text Add to dashboard Cite

In clinical practice, xerostomia or oral dryness is a chronic disease condition encountered by most dentists and dental hygienists, which often causes a negative impact on the oral health-related quality of life of the affected individual. Xerostomia is caused due to salivary gland dysfunction. It is related to reduced salivary secretion or the absence of saliva flow, more frequently, exhibits qualitative changes in saliva proteins and immunoglobulin concentrations that arise due to salivary gland dysfunction. This condition causes discomfort and interferes with normal oral activities, and affected individuals are at high caries risk. There are several options for treatment and symptom management: salivary stimulants, topical agents, saliva substitutes, and systemic sialogogues. This review explores the current status of therapeutic management of patients affected by xerostomia and hyposalivation using artificial saliva.

show abstract

Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren’s syndrome

Cited by 8 publications

References 12 publications

The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology

The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology

The Future of Targeted Treatment of Primary Sjögren's Syndrome: A Focus on Extra-Glandular Pathology

Artificial Saliva for Therapeutic Management of Xerostomia

Contact Info

Product

Resources

About